Lung Diseases, Obstructive clinical trials

The registry lists 202 studies for Lung Diseases, Obstructive across more than 10 countries. 22 are recruiting or about to start. 50 of them are mainly about Lung Diseases, Obstructive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 11 narrower conditions too, such as Pulmonary Disease, Chronic Obstructive: 11,199 studies, 1,578 open.

Get an email when these change. Save the Lung Diseases, Obstructive studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 141
Status unknown: 17
Recruiting: 15
Terminated: 10
Not yet recruiting: 7
Active, not recruiting: 6

Phase

Phase 3: 37
Phase 2: 23
Phase 4: 18
Phase 1: 6
Early Phase 1: 1

Where

United States: 64
Germany: 25
Canada: 19
United Kingdom: 19
France: 18
Poland: 14

Who runs them

National Heart, Lung, and Blood Institute (NHLBI) (25) · AstraZeneca (20) · University of Zurich (7) · University of Michigan (5) · Royal Brompton & Harefield NHS Foundation Trust (4) · Novartis Pharmaceuticals (4) · Radboud University Medical Center (3) · Columbia University (3)

What is being tested here

Drugs under test in Lung Diseases, Obstructive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
GSK3862995B	1	0	1
Felcorekibart	1	0	1
AERO-002	1	0	1
Vimseltinib	1	0	1
Benralizumab	0	12	12
Glycopyrrolate	0	2	4
Acetazolamide	0	0	3
Azithromycin	0	0	2
Tralokinumab	0	2	2
PF-610355	0	0	2

Drug classes tested here Corticosteroids 5 · Antimuscarinics 5 · Bronchodilators 4

Coming up

1phase 3 study under way

8studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Sep 2027A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) · Phase 3 · Grifols Therapeutics LLC
Dec 2026Secondhand Smoke Respiratory Health Study · University of California, San Francisco
Apr 2027Effect of Dietary Fiber Supplementation on Systemic Inflammation and Clinical Parameters in COPD · Júnea Regina Pires Drews
Jun 2027Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients · AeroRx Therapeutics Inc.
Jun 2027Cough Capture as a Portal Into the Lung · Albert Einstein College of Medicine
Jun 2027TCM Daoyin Therapy in Individuals At-risk for COPD · Shanghai University of Traditional Chinese Medicine
Aug 2027Measurement of Viscoelastic Properties of Bronchopulmonary Secretions. · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Nov 2027Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway. · Centre Hospitalier Universitaire de Nīmes

Who these studies take

Of the 15 Lung Diseases, Obstructive studies recruiting now, 10 (67%) set no upper age limit and 2 (13%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (27%) take healthy volunteers.

Recruiting studies that take each age, of 15
Age	Women	Men
10	0 (0%)	0 (0%)
18	10 (67%)	10 (67%)
30	12 (80%)	12 (80%)
40	15 (100%)	15 (100%)
50	15 (100%)	15 (100%)
65	14 (93%)	14 (93%)
75	14 (93%)	14 (93%)
85	12 (80%)	12 (80%)

Across all 202 studies, recruiting or not: 29% stop at 75 or younger and 10% at 65; 26% take children; 1% are for women only and 8% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Diseases, Obstructive studies take

Of 15 phase 3 interventional studies under Lung Diseases, Obstructive, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 3	27 mo20–45 · 15 studies	—	—
Interventional, no phase	25 mo11–39 · 28 studies	—	—
Observational	27 mo11–53 · 25 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

THERMotherapy Against Persistent Bacterial LUNG InfectionsNov 6, 2026NCT05351242
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD PatientsOct 28, 2026NCT07896252

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 202. Browse all 202 → or search them.